The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: RepliCel Life Sciences

Monday Deal Review: January 13, 2014

  Welcome to your Monday Biotech Deal Review for Janary 13, 2014! This week saw the closing of a number of financing transactions, as well as Sirona’s announcement of a private placement of up to $5.34 million in proceeds.  Aeterna Zentaris also announced pricing of their public offering, indicating that shares will be sold at US$1.20 per share, with proceeds up to US$12.2 million.

For details on these deals, as well as the rest of the week’s major biotech news, hit the break.

Read more of this post

Monday Deal Review: September 9, 2013

Welcome to your Monday Biotech Deal Review for September 9, 2013! This week saw Medicago recieve the shareholder approval it needed in order to continue its arrangement with MTPC.  Cash consideration of $1.16 will be given for each share of Medicago.

For more detail on this deal, as well as the rest of the major recent biotech stories, hit the break!

Read more of this post

Monday Deal Review: August 19, 2013

Welcome to your Monday Biotech Deal Review for August 19, 2013! As August comes to a close, activity is beginning to pick up.  Bellus and Valeant have closed their acquisitions of Thallion and Bausch + Lomb, respectively.  On the financing side of things, Sophiris and Covalon are pursuing offerings, with Sophiris looking at rasing $65 million.  Finally, Transition, Vivione and Quest PharmaTech have executed deals for licensing or development.

Hit the break to see the whole story on these major deals and for the rest of the past weeks’ stories!

Read more of this post

Monday Deal Review: July 22, 2013

Welcome to your Monday Biotech Deal Review for July 22, 2013! A busy week saw acquisitions of Medicago by Mitsubishi Tanabe Pharma Corporation and Allon’s acquisition by Paladin Labs.

Hit the break to see the whole story on these major deals and for the rest of the past weeks’ stories!

Read more of this post

Monday Deal Review: February 18, 2013

Welcome to your Monday Biotech Deal Review for February 18, 2013! This week saw Gilead finally close its acquisition of YM Biosciences, with YM’s shares now de-listed from trading on the NYSE Amex and the TSX. Shareholders were given $2.65 for each of their common shares during the plan of arrangement.  On the investment front, Innovotech, RepliCel, Lignol, Biosenta and Biosign each had announcements relating to the close or amendment of existing private placements.  Click on to see the full details.

Read more of this post

Monday Biotech Deal Review: April 23, 2012

Welcome to your Monday Biotech Deal Review for April 23, 2012.  Deals from the past week were slow, but included a $10M brokered private placement by Allon Therapeutics and the completion of Warnex’ new credit facility.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: April 2, 2012

Welcome to your Monday Biotech Deal Review for April 2, 2012.  There have been few large transactions over the previous weeks, but there have been some private placement financings and M&A activity, including the announcement of a takeover by Valeant of Russian-based Natur Product International for approximately $180M.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: November 28, 2011

Welcome to your Monday Biotech Deal Review for November 28, 2011.  Notable events from the previous week include the announcement of a fully-subscribed brokered private placement by Resverlogix for proceeds of $17.5 million, as well as the announcement by Valeant of an agreement to acquire iNova (Valeant’s appetite for acquisitions continues, unabated), a prescription and OTC seller and distributor operating in the Asia Pacific region and South Africa.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: July 11, 2011

Welcome to your Monday Biotech Deal Review for July 11, 2011.  This week is a double feature, owing to last week’s break due to both Canada Day and Fourth of July holidays.  There was a lot of activity over the past two weeks in the biotech space.   Read on to catch up!  Read more of this post

Follow

Get every new post delivered to your Inbox.

Join 130 other followers